Phase I study of fluorapacin in combination with pemetrexed in patients with advanced non-small cell lung cancer

Trial Profile

Phase I study of fluorapacin in combination with pemetrexed in patients with advanced non-small cell lung cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Fluorapacin (Primary) ; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 28 Sep 2017 New trial record
    • 01 Sep 2017 Results published in the Clinical Pharmacology in Drug Development: 2017 Annual Meeting of the American College of Clinical Pharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top